We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Bempedoic Acidis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Bempedoic Acid studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2016–2023 with a typical study size of 2,230 participants.
Based on 7 studies · 1 meta-analysis · 5 RCTs · 21,413 total participants
Confidence
HighBy outcome
Bempedoic Acid has an evidence score of 4.3/10 — strong evidence based on 7 indexed studies, including 1 meta-analysis. An FDA-approved oral LDL-cholesterol-lowering drug (Nexletol) that inhibits ATP-citrate lyase (ACL) upstream of statins in the cholesterol-synthesis pathway. Because it is a prodrug activated in the liver — not muscle — it largely avoids statin-type muscle pain, making it a key option for statin-intolerant patients. The landmark CLEAR Outcomes RCT (~14,000 patients) showed reduced major cardiovascular events. Lowers LDL-C ~15-25% as monotherapy. Raises uric acid (gout), liver enzymes, and carries a small tendon-rupture signal. Prescription drug, not a supplement. Representative study: PMID 32673317.
The commonly studied dose of Bempedoic Acid is 180 mg orally once daily, with or without food, under a clinician. Available alone (Nexletol) or co-formulated with ezetimibe 10 mg (Nexlizet). A prescription drug — dosing is set by a prescriber.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Alirocumab (Praluent)
Notable regimens that report including Bempedoic Acid — documented, not endorsed.
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Bempedoic Acid (Nexletol) — ATP-citrate lyase inhibitor
An FDA-approved oral LDL-cholesterol-lowering drug (Nexletol) that inhibits ATP-citrate lyase (ACL) upstream of statins in the cholesterol-synthesis pathway. Because it is a prodrug activated in the liver — not muscle — it largely avoids statin-type muscle pain, making it a key option for statin-intolerant patients. The landmark CLEAR Outcomes RCT (~14,000 patients) showed reduced major cardiovascular events. Lowers LDL-C ~15-25% as monotherapy. Raises uric acid (gout), liver enzymes, and carries a small tendon-rupture signal. Prescription drug, not a supplement.
Bempedoic acid has strong, consistent human evidence: a coordinated phase-3 LDL-lowering program (CLEAR Harmony/Wisdom/Serenity/Tranquility) plus the landmark CLEAR Outcomes RCT (~14,000 statin-intolerant patients) showing reduced major adverse cardiovascular events. LDL reductions are moderate (~15-25% monotherapy) rather than statin-level, and it carries gout/uric-acid, liver-enzyme, creatinine, and small tendon-rupture risks — so a strong but not perfect score.
Bempedoic acid is an FDA-approved oral lipid-lowering drug (Nexletol; co-formulated with ezetimibe as Nexlizet) that inhibits ATP-citrate lyase (ACL), an enzyme that sits upstream of HMG-CoA reductase in the hepatic cholesterol-synthesis pathway.
Inhibiting ACL reduces cholesterol synthesis, which upregulates LDL receptors and clears LDL particles from the blood — the same downstream mechanism statins exploit, but at a different step.
Its defining feature is that it is a prodrug activated by an enzyme (very-long-chain acyl-CoA synthetase-1) that is expressed in the liver but essentially absent from skeletal muscle, so the active drug is not generated in muscle tissue.
This is why bempedoic acid largely avoids the myalgia and muscle complaints that lead many patients to discontinue statins, and it is positioned primarily for statin-intolerant patients or as add-on therapy when statins plus ezetimibe do not reach LDL goals.
As monotherapy it lowers LDL-C roughly 15-25%, with larger reductions when combined with ezetimibe.
The evidence base is genuinely strong for a lipid drug: a coordinated phase-3 program (CLEAR Harmony, CLEAR Wisdom, CLEAR Serenity, CLEAR Tranquility) established consistent LDL-lowering and tolerability, and the landmark CLEAR Outcomes cardiovascular-outcomes trial (~14,000 statin-intolerant patients) demonstrated a significant reduction in major adverse cardiovascular events.
The honest caveats: bempedoic acid raises uric acid and can precipitate gout, modestly raises liver enzymes, can raise creatinine, and carries a small increased risk of tendon rupture; CLEAR Outcomes also saw slightly higher rates of gout and gallstones (cholelithiasis).
It is a real, effective prescription drug with a favorable but not risk-free profile — not a supplement, and not a longevity or off-label optimization compound.
Inhibits ACL, an enzyme upstream of HMG-CoA reductase in hepatic cholesterol synthesis, reducing cholesterol production and upregulating LDL receptors to clear LDL from the blood.
Activated by acyl-CoA synthetase-1, which is present in liver but essentially absent in skeletal muscle — so the active drug is not formed in muscle, largely avoiding statin-type myalgia.
Lower hepatic cholesterol synthesis upregulates LDL receptors, increasing clearance of circulating LDL-C and lowering it ~15-25% as monotherapy.
How Bempedoic Acid works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
180 mg orally once daily, with or without food, under a clinician. Available alone (Nexletol) or co-formulated with ezetimibe 10 mg (Nexlizet). A prescription drug — dosing is set by a prescriber.
Loading: No loading dose; a fixed 180 mg once-daily tablet is used.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral tablet (bempedoic acid 180 mg) | Recommended |
| 💊Bempedoic acid + ezetimibe fixed-dose (Nexlizet) for greater LDL lowering | Alternative |
Bempedoic acid is the ACL inhibitor; the ezetimibe combination adds intestinal cholesterol-absorption blockade for a larger LDL reduction.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Once daily, with or without food. Lipid effect is established by ~12 weeks; cardiovascular benefit accrues over months to years of continuous use.
Dose-response data unavailable. The current published research for Bempedoic Acid does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Lowers LDL-C roughly 15-25% as monotherapy and more in combination with ezetimibe.
CLEAR Outcomes showed a significant reduction in major adverse cardiovascular events in statin-intolerant patients.
Not activated in muscle, so it largely avoids the myalgia that limits statins — its main advantage for statin-intolerant patients.
Raises serum uric acid and can precipitate gout; CLEAR Outcomes saw higher gout incidence.
Carries a small increased risk of tendon rupture, particularly in older patients or those on corticosteroids/fluoroquinolones.
Can modestly raise liver transaminases and serum creatinine; uric acid and gallstone (cholelithiasis) signals were noted.
Use with caution — bempedoic acid raises uric acid and can precipitate flares; monitor and manage.
Counsel on tendon-rupture warning signs and discontinue promptly if they occur.
Observe statin dose limits to avoid myopathy from raised statin levels.
Bempedoic acid raises blood levels of these statins, increasing myopathy risk — dose limits apply.
May add to the small tendon-rupture risk.
Tip: Monitor uric acid; treat gout flares; caution in patients with a gout history.
Tip: Check liver enzymes at baseline and periodically; creatinine rise is usually small and non-progressive.
Tip: Discontinue at the first sign of tendon pain or swelling; higher risk in older adults and with corticosteroids/fluoroquinolones.
Timing is flexible for Bempedoic Acid — consistent daily use matters more than the time of day. Once daily, with or without food; consistency matters more than timing.
Bempedoic Acid is generally safe at recommended doses, with a few precautions worth noting. The most commonly reported side effects are hyperuricemia / gout, raised liver enzymes / creatinine, tendon rupture. Use caution if any of these apply to you: Concurrent simvastatin >20 mg or pravastatin >40 mg (bempedoic acid raises their levels); Active gout flare without management; History of tendon rupture related to similar agents.
A fully human monoclonal-antibody PCSK9 inhibitor (Praluent), injected under the skin every 2 weeks, that lowers LDL cholesterol by ~50–60%. In the ODYSSEY OUTCOMES trial of ~18,900 post-heart-attack patients it reduced major cardiovascular events and showed a possible all-cause mortality signal. Generally well tolerated; injection-site reactions and high cost/access are the main trade-offs. Prescription drug, not a supplement.